Previous 10 | Next 10 |
AC Immune (NASDAQ:ACIU) reported interim 10-week data from a high-dose cohort of a phase 1b/2a trial evaluating ACI-35.030, a phosphorylated-Tau (pTau) vaccine candidate in people with early Alzheimer’s disease (AD). The company said new interim data showed that the high-dose of A...
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to date Interim data support plans f...
AC Immune (NASDAQ:ACIU) will advance an optimized version of ACI-24, currently in preclinical stage, into the clinic for Alzheimer's disease. The decision is supported by data published in the journal Brain Communications that showed an optimized ACI-24 vaccine formulation induced a broad pol...
Snap (NYSE:SNAP) +40% on Q4 results. Bill.com Holdings (NYSE:BILL) +23% on Q2 results. Sphere 3D (NASDAQ:ANY) +16% on purchase of 60K Numiner NM440 BTC Miners. Unity Software (NYSE:U) +14% on Q4 results. Standard Lithium (NYSE:SLI) +12% set to rebound from short seller's s...
Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support advancing optimized ACI-24 into the next stage of clinical development for A...
LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor ...
Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD) Programs targeting intracellular disease mechanisms complement AC Immune’s extensive P...
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14 th CTAD conference support ACI-35.030’s advancement into late-stage development LAUSANNE, Switzerland, Nov. 12, 2021 (GLOBE ...
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo Benefit of semorinemab on ADAS-Cog11 in al...
AC Immune (NASDAQ:ACIU): Q3 GAAP EPS of -CHF0.22. The Company had a total cash balance of CHF188.6M, composed of CHF93.6M in cash and cash equivalents and CHF95.0M in short-term financial assets.. Shares +10.1% PM. Press Release For further details see: AC Immune EPS beats by $0.08...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...